{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:17:35Z","timestamp":1784618255532,"version":"3.55.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Geri Rep"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s13670-019-0269-1","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T11:03:39Z","timestamp":1551697419000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pharmacologic Management of Agitation in Patients with Dementia"],"prefix":"10.1007","volume":"8","author":[{"given":"Cara L.","family":"McDermott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Gruenewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"issue":"19","key":"269_CR1","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"LE Hebert","year":"2013","unstructured":"Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80(19):1778\u201383.","journal-title":"Neurology"},{"issue":"11","key":"269_CR2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaneurol.2017.1964","volume":"74","author":"CA Derby","year":"2017","unstructured":"Derby CA, Katz MJ, Lipton RB, Hall CB. Trends in dementia incidence in a birth cohort analysis of the Einstein aging study. JAMA Neurol. 2017;74(11):1345\u201351.","journal-title":"JAMA Neurol"},{"issue":"1","key":"269_CR3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jalz.2010.11.002","volume":"7","author":"WA Rocca","year":"2011","unstructured":"Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DA, Hall KS, et al. Trends in the incidence and prevalence of Alzheimer\u2019s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 2011;7(1):80\u201393.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"269_CR4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.bp.114.148403","volume":"209","author":"RM Linde van der","year":"2016","unstructured":"van der Linde RM, Dening T, Stephan BC, Prina AM, Evans E, Brayne C. Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. Br J Psychiatry. 2016;209(5):366\u201377.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"269_CR5","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1192\/bjp.bp.113.141119","volume":"205","author":"G Livingston","year":"2014","unstructured":"Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014;205(6):436\u201342.","journal-title":"Br J Psychiatry"},{"key":"269_CR6","first-page":"218980","volume":"2015","author":"AM Oliveira de","year":"2015","unstructured":"de Oliveira AM, Radanovic M, de Mello PC, Buchain PC, Vizzotto AD, Celestino DL, et al. Nonpharmacological interventions to reduce behavioral and psychological symptoms of dementia: a systematic review. Biomed Res Int. 2015;2015:218980.","journal-title":"Biomed Res Int"},{"key":"269_CR7","volume-title":"Nonpharmacologic interventions for agitation and aggression in dementia","author":"M Brasure","year":"2016","unstructured":"Brasure M, Jutkowitz E, Fuchs E, Nelson VA, Kane RA, Shippee T, et al. Nonpharmacologic interventions for agitation and aggression in dementia. Rockville (MD): AHRQ Comparative Effectiveness Reviews; 2016."},{"issue":"10","key":"269_CR8","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jagp.2017.02.025","volume":"25","author":"DT Maust","year":"2017","unstructured":"Maust DT, Kales HC, McCammon RJ, Blow FC, Leggett A, Langa KM. Distress associated with dementia-related psychosis and agitation in relation to healthcare utilization and costs. Am J Geriatr Psychiatry. 2017;25(10):1074\u201382.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"269_CR9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/jgs.12694","volume":"62","author":"BT Suehs","year":"2014","unstructured":"Suehs BT, Shah SN, Davis CD, Alvir J, Faison WE, Patel NC, et al. Household members of persons with Alzheimer\u2019s disease: health conditions, healthcare resource use, and healthcare costs. J Am Geriatr Soc. 2014;62(3):435\u201341.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"269_CR10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/cns.12076","volume":"19","author":"JL Cummings","year":"2013","unstructured":"Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg\/day) for the treatment of moderate and severe Alzheimer\u2019s disease: drug profile and clinical guidelines. CNS Neurosci Ther. 2013;19(5):294\u2013301.","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"269_CR11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cns.12484","volume":"22","author":"J Cummings","year":"2016","unstructured":"Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G, et al. Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer\u2019s disease and dementia with Lewy bodies. CNS Neurosci Ther. 2016;22(3):159\u201366.","journal-title":"CNS Neurosci Ther"},{"issue":"9247","key":"269_CR12","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","volume":"356","author":"I McKeith","year":"2000","unstructured":"McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031\u20136.","journal-title":"Lancet"},{"issue":"12","key":"269_CR13","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1001\/archneur.60.12.1745","volume":"60","author":"NI Bohnen","year":"2003","unstructured":"Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60(12):1745\u20138.","journal-title":"Arch Neurol"},{"issue":"1","key":"269_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jnnp-2014-308112","volume":"86","author":"J Wang","year":"2015","unstructured":"Wang J, Yu JT, Wang HF, Meng XF, Wang C, Tan CC, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer\u2019s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(1):101\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"269_CR15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JAD-131190","volume":"39","author":"E Cumbo","year":"2014","unstructured":"Cumbo E, Ligori LD. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer\u2019s disease: a 12-month, randomized, open-label trial. J Alzheimers Dis. 2014;39(3):477\u201385.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"269_CR16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3233\/JAD-160675","volume":"56","author":"A Carotenuto","year":"2017","unstructured":"\u2022\u2022 Carotenuto A, Rea R, Traini E, Fasanaro AM, Ricci G, Manzo V, et al. The effect of the association between donepezil and choline alphoscerate on behavioral disturbances in Alzheimer\u2019s disease: interim results of the ASCOMALVA trial. J Alzheimers Dis. 2017;56(2):805\u201315 Interim results suggest addition of choline alphoscerate may result in reduced BPSD and decreased accompanying caregiver distress in patients with mild-moderate AD.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"269_CR17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3233\/JAD-132735","volume":"41","author":"P Gareri","year":"2014","unstructured":"Gareri P, Putignano D, Castagna A, Cotroneo AM, De Palo G, Fabbo A, et al. Retrospective study on the benefits of combined memantine and cholinesterase inhibitor treatMent in AGEd patients affected with Alzheimer\u2019s disease: the MEMAGE study. J Alzheimers Dis. 2014;41(2):633\u201340.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"269_CR18","doi-asserted-by":"crossref","first-page":"e0183586","DOI":"10.1371\/journal.pone.0183586","volume":"12","author":"R Chen","year":"2017","unstructured":"\u2022 Chen R, Chan PT, Chu H, Lin YC, Chang PC, Chen CY, et al. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: a meta-analysis. PLoS One. 2017;12(8):e0183586 Analysis notes greater improvement in BPSD for patients with severe AD receiving combination therapy vs donepezil only.","journal-title":"PLoS One"},{"issue":"3","key":"269_CR19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ggi.12754","volume":"17","author":"SJ Yoon","year":"2017","unstructured":"Yoon SJ, Choi SH, Na HR, Park KW, Kim EJ, Han HJ, et al. Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer\u2019s disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon patch and combination with mEmantine comparative trial study). Geriatr Gerontol Int. 2017;17(3):494\u20139.","journal-title":"Geriatr Gerontol Int"},{"issue":"3","key":"269_CR20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/psyg.12140","volume":"16","author":"Y Manabe","year":"2016","unstructured":"Manabe Y, Ino T, Yamanaka K, Kosaka K. Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies. Psychogeriatrics. 2016;16(3):202\u20138.","journal-title":"Psychogeriatrics"},{"issue":"4","key":"269_CR21","doi-asserted-by":"crossref","first-page":"371 e11","DOI":"10.1016\/j.jamda.2017.12.098","volume":"19","author":"LJ Seppala","year":"2018","unstructured":"Seppala LJ, Wermelink A, de Vries M, Ploegmakers KJ, van de Glind EMM, Daams JG, et al. Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics. J Am Med Dir Assoc. 2018;19(4):371 e11\u20137.","journal-title":"J Am Med Dir Assoc"},{"key":"269_CR22","first-page":"CD008191","volume":"2","author":"DP Seitz","year":"2011","unstructured":"Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;2:CD008191.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"269_CR23","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"\u2022\u2022 Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682\u201391 RCT demonstrated efficacy of citalopram for management of BPSD.","journal-title":"JAMA"},{"issue":"7","key":"269_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17070","volume":"17","author":"S Banerjee","year":"2013","unstructured":"Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess. 2013;17(7):1\u2013166.","journal-title":"Health Technol Assess"},{"issue":"1","key":"269_CR25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/gps.4566","volume":"32","author":"N Farina","year":"2017","unstructured":"Farina N, Morrell L, Banerjee S. What is the therapeutic value of antidepressants in dementia? A narrative review. Int J Geriatr Psychiatry. 2017;32(1):32\u201349.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"269_CR26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1017\/S1041610216002441","volume":"29","author":"MR Santa Cruz","year":"2017","unstructured":"Santa Cruz MR, Hidalgo PC, Lee MS, Thomas CW, Holroyd S. Buspirone for the treatment of dementia with behavioral disturbance. Int Psychogeriatr. 2017;29(5):859\u201362.","journal-title":"Int Psychogeriatr"},{"issue":"2","key":"269_CR27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.pnpbp.2008.12.019","volume":"33","author":"K Mizukami","year":"2009","unstructured":"Mizukami K, Hatanaka K, Tanaka Y, Sato S, Asada T. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer\u2019s disease. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33(2):349\u201352.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"4\u20135","key":"269_CR28","first-page":"131","volume":"47","author":"N Mokhber","year":"2014","unstructured":"Mokhber N, Abdollahian E, Soltanifar A, Samadi R, Saghebi A, Haghighi MB, et al. Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. Pharmacopsychiatry. 2014;47(4\u20135):131\u201340.","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"269_CR29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/13554794.2016.1211711","volume":"22","author":"CP Lin","year":"2016","unstructured":"Lin CP, Chu CP, Liu HC. Bupropion improved apathy in behavioral variant frontotemporal dementia: a case report. Neurocase. 2016;22(5):466\u20138.","journal-title":"Neurocase"},{"key":"269_CR30","first-page":"CD004990","volume":"4","author":"G Martinon-Torres","year":"2004","unstructured":"Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev. 2004;4:CD004990.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"269_CR31","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jagp.2013.12.174","volume":"22","author":"EF Camargos","year":"2014","unstructured":"Camargos EF, Louzada LL, Quintas JL, Naves JO, Louzada FM, Nobrega OT. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. 2014;22(12):1565\u201374.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"7","key":"269_CR32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1533317514524813","volume":"29","author":"RR Tampi","year":"2014","unstructured":"Tampi RR, Tampi DJ. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2014;29(7):565\u201374.","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"10","key":"269_CR33","doi-asserted-by":"crossref","first-page":"pyv055","DOI":"10.1093\/ijnp\/pyv055","volume":"18","author":"M Defrancesco","year":"2015","unstructured":"Defrancesco M, Marksteiner J, Fleischhacker WW, Blasko I. Use of benzodiazepines in Alzheimer\u2019s disease: a systematic review of literature. Int J Neuropsychopharmacol. 2015;18(10):pyv055.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"269_CR34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/2040622316658463","volume":"7","author":"RR Tampi","year":"2016","unstructured":"Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229\u201345.","journal-title":"Ther Adv Chronic Dis"},{"key":"269_CR35","doi-asserted-by":"crossref","unstructured":"Kane JM, Correll CU, Nierenberg AA, Caroff SN, Sajatovic M, Tardive Dyskinesia Assessment Working G. Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop. J Clin Psychiatry. 2018;79(3).","DOI":"10.4088\/JCP.17cs11959"},{"key":"269_CR36","first-page":"CD007726","volume":"3","author":"E Leeuwen Van","year":"2018","unstructured":"Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AI, Vander Stichele R, Declercq T, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018;3:CD007726.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"269_CR37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4140\/TCP.n.2015.599","volume":"30","author":"J Tjia","year":"2015","unstructured":"\u2022 Tjia J, Reidenberg MM, Hunnicutt JN, Paice K, Donovan JL, Kanaan A, et al. Approaches to gradual dose reduction of chronic off-label antipsychotics used for behavioral and psychological symptoms of dementia. Consult Pharm. 2015;30(10):599\u2013611 Synthesizes data supporting proposed de-prescribing algorithm for patients receiving anti-psychotics.","journal-title":"Consult Pharm"},{"issue":"3","key":"269_CR38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.9740\/mhc.2018.05.122","volume":"8","author":"M Mathys","year":"2018","unstructured":"Mathys M, Fang S, John J, Carter J. Antipsychotic discontinuation after the initiation of selective serotonin reuptake inhibitors therapy for the treatment of behavioral and psychological symptoms associated with dementia. Ment Health Clin. 2018;8(3):122\u20136.","journal-title":"Ment Health Clin"},{"issue":"7","key":"269_CR39","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jamda.2018.05.002","volume":"19","author":"H Brodaty","year":"2018","unstructured":"\u2022\u2022 Brodaty H, Aerts L, Harrison F, Jessop T, Cations M, Chenoweth L, et al. Antipsychotic deprescription for older adults in long-term care: the HALT study. J Am Med Dir Assoc. 2018;19(7):592\u2013600 e7 Demonstrated that anti-psychotics may be safely withdrawn without increase in BPSD or adverse outcomes.","journal-title":"J Am Med Dir Assoc"},{"issue":"8","key":"269_CR40","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","volume":"68","author":"PN Tariot","year":"2011","unstructured":"Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011;68(8):853\u201361.","journal-title":"Arch Gen Psychiatry"},{"key":"269_CR41","first-page":"CD003945","volume":"3","author":"E Lonergan","year":"2009","unstructured":"Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2009;3:CD003945.","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"269_CR42","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s40265-014-0293-6","volume":"74","author":"D Gallagher","year":"2014","unstructured":"Gallagher D, Herrmann N. Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy? Drugs. 2014;74(15):1747\u201355.","journal-title":"Drugs"},{"issue":"1","key":"269_CR43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/psyg.12085","volume":"15","author":"H Suzuki","year":"2015","unstructured":"Suzuki H, Gen K. Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer\u2019s disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial. Psychogeriatrics. 2015;15(1):32\u20137.","journal-title":"Psychogeriatrics"},{"issue":"2","key":"269_CR44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1176\/appi.neuropsych.12050115","volume":"25","author":"C Cooney","year":"2013","unstructured":"Cooney C, Murphy S, Tessema H, Freyne A. Use of low-dose gabapentin for aggressive behavior in vascular and mixed vascular\/Alzheimer dementia. J Neuropsychiatry Clin Neurosci. 2013;25(2):120\u20135.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"12","key":"269_CR45","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.2015.10214","volume":"314","author":"JL Cummings","year":"2015","unstructured":"\u2022\u2022 Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242\u201354 In short-term 10 week trial, authors found reduced agitation among AD patients taking dextromethorphan-quinidine.","journal-title":"JAMA"},{"key":"269_CR46","doi-asserted-by":"crossref","first-page":"212508","DOI":"10.7573\/dic.212508","volume":"6","author":"RR Tampi","year":"2017","unstructured":"Tampi RR, Hassell C, Joshi P, Tampi DJ. Analgesics in the management of behavioral and psychological symptoms of dementia: a perspective review. Drugs Context. 2017;6:212508.","journal-title":"Drugs Context"},{"key":"269_CR47","doi-asserted-by":"crossref","first-page":"7036415","DOI":"10.1155\/2016\/7036415","volume":"2016","author":"TF Habiger","year":"2016","unstructured":"Habiger TF, Flo E, Achterberg WP, Husebo BS. The interactive relationship between pain, psychosis, and agitation in people with dementia: results from a cluster-randomised clinical trial. Behav Neurol. 2016;2016:7036415.","journal-title":"Behav Neurol"},{"key":"269_CR48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cct.2018.05.019","volume":"71","author":"DP Devanand","year":"2018","unstructured":"Devanand DP, Strickler JG, Huey ED, Crocco E, Forester BP, Husain MM, et al. Lithium treatment for agitation in Alzheimer\u2019s disease (lit-AD): clinical rationale and study design. Contemp Clin Trials. 2018;71:33\u20139.","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"269_CR49","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/phar.1943","volume":"37","author":"CN Carr","year":"2017","unstructured":"Carr CN, Straley CM, Baugh TB. Allopurinol for the treatment of refractory aggression: a case series. Pharmacotherapy. 2017;37(6):748\u201354.","journal-title":"Pharmacotherapy"},{"key":"269_CR50","first-page":"947","volume":"9","author":"AG Wade","year":"2014","unstructured":"Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer\u2019s disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014;9:947\u201361.","journal-title":"Clin Interv Aging"},{"issue":"11","key":"269_CR51","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/j.clinthera.2016.09.010","volume":"38","author":"JL Schroeck","year":"2016","unstructured":"Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, et al. Review of safety and efficacy of sleep medicines in older adults. Clin Ther. 2016;38(11):2340\u201372.","journal-title":"Clin Ther"},{"key":"269_CR52","first-page":"CD009178","volume":"11","author":"J McCleery","year":"2016","unstructured":"McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2016;11:CD009178.","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"269_CR53","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1212\/WNL.0000000000001617","volume":"84","author":"J Butchart","year":"2015","unstructured":"Butchart J, Brook L, Hopkins V, Teeling J, Puntener U, Culliford D, et al. Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015;84(21):2161\u20138.","journal-title":"Neurology"},{"issue":"9","key":"269_CR54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11940-016-0425-2","volume":"18","author":"R Giorgi De","year":"2016","unstructured":"De Giorgi R, Series H. Treatment of inappropriate sexual behavior in dementia. Curr Treat Options Neurol. 2016;18(9):41.","journal-title":"Curr Treat Options Neurol"},{"issue":"6","key":"269_CR55","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-151-6-200909150-00007","volume":"151","author":"TE Quill","year":"2009","unstructured":"Quill TE, Lo B, Brock DW, Meisel A. Last-resort options for palliative sedation. Ann Intern Med. 2009;151(6):421\u20134.","journal-title":"Ann Intern Med"},{"issue":"4","key":"269_CR56","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jpainsymman.2013.05.015","volume":"47","author":"SA Hendriks","year":"2014","unstructured":"Hendriks SA, Smalbrugge M, Hertogh CM, van der Steen JT. Dying with dementia: symptoms, treatment, and quality of life in the last week of life. J Pain Symptom Manag. 2014;47(4):710\u201320.","journal-title":"J Pain Symptom Manag"},{"key":"269_CR57","doi-asserted-by":"crossref","unstructured":"Benitez-Rosario MA, Morita T. Palliative sedation in clinical scenarios: results of a modified Delphi study. Support Care Cancer. 2018.","DOI":"10.1007\/s00520-018-4409-5"},{"issue":"Suppl 3","key":"269_CR58","doi-asserted-by":"crossref","first-page":"iii143","DOI":"10.1093\/annonc\/mdu238","volume":"25","author":"NI Cherny","year":"2014","unstructured":"Cherny NI, Group EGW. ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation. Ann Oncol. 2014;25(Suppl 3):iii143\u201352.","journal-title":"Ann Oncol"},{"issue":"6","key":"269_CR59","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/1049909114533002","volume":"32","author":"L Gurschick","year":"2015","unstructured":"Gurschick L, Mayer DK, Hanson LC. Palliative sedation: an analysis of international guidelines and position statements. Am J Hosp Palliat Care. 2015;32(6):660\u201371.","journal-title":"Am J Hosp Palliat Care"},{"issue":"1","key":"269_CR60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/15360288.2017.1279502","volume":"31","author":"J Bodnar","year":"2017","unstructured":"Bodnar J. A review of agents for palliative sedation\/continuous deep sedation: pharmacology and practical applications. J Pain Palliat Care Pharmacother. 2017;31(1):16\u201337.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"23","key":"269_CR61","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","volume":"84","author":"GA Elsen van den","year":"2015","unstructured":"van den Elsen GA, Ahmed AI, Verkes RJ, Kramers C, Feuth T, Rosenberg PB, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology. 2015;84(23):2338\u201346.","journal-title":"Neurology"},{"issue":"3","key":"269_CR62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1017\/S1041610217001892","volume":"30","author":"E Savaskan","year":"2018","unstructured":"Savaskan E, Mueller H, Hoerr R, von Gunten A, Gauthier S. Treatment effects of Ginkgo biloba extract EGb 761(R) on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials. Int Psychogeriatr. 2018;30(3):285\u201393.","journal-title":"Int Psychogeriatr"},{"key":"269_CR63","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1472-6882-13-165","volume":"13","author":"CY Fu","year":"2013","unstructured":"Fu CY, Moyle W, Cooke M. A randomised controlled trial of the use of aromatherapy and hand massage to reduce disruptive behaviour in people with dementia. BMC Complement Altern Med. 2013;13:165.","journal-title":"BMC Complement Altern Med"},{"issue":"12","key":"269_CR64","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1089\/acm.2015.0158","volume":"21","author":"K Yoshiyama","year":"2015","unstructured":"Yoshiyama K, Arita H, Suzuki J. The effect of aroma hand massage therapy for people with dementia. J Altern Complement Med. 2015;21(12):759\u201365.","journal-title":"J Altern Complement Med"},{"key":"269_CR65","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/1472-6882-13-315","volume":"13","author":"DW O\u2019Connor","year":"2013","unstructured":"O\u2019Connor DW, Eppingstall B, Taffe J, van der Ploeg ES. A randomized, controlled cross-over trial of dermally-applied lavender (Lavandula angustifolia) oil as a treatment of agitated behaviour in dementia. BMC Complement Altern Med. 2013;13:315.","journal-title":"BMC Complement Altern Med"},{"key":"269_CR66","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12906-015-0612-9","volume":"15","author":"MH Yang","year":"2015","unstructured":"Yang MH, Lin LC, Wu SC, Chiu JH, Wang PN, Lin JG. Comparison of the efficacy of aroma-acupressure and aromatherapy for the treatment of dementia-associated agitation. BMC Complement Altern Med. 2015;15:93.","journal-title":"BMC Complement Altern Med"},{"issue":"2","key":"269_CR67","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ggi.12696","volume":"17","author":"K Furukawa","year":"2017","unstructured":"Furukawa K, Tomita N, Uematsu D, Okahara K, Shimada H, Ikeda M, et al. Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer\u2019s disease. Geriatr Gerontol Int. 2017;17(2):211\u20138.","journal-title":"Geriatr Gerontol Int"},{"issue":"5","key":"269_CR68","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/JCP.0b013e31829798d5","volume":"33","author":"M Teranishi","year":"2013","unstructured":"Teranishi M, Kurita M, Nishino S, Takeyoshi K, Numata Y, Sato T, et al. Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial. J Clin Psychopharmacol. 2013;33(5):600\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"269_CR69","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/0269881117744996","volume":"32","author":"SJ Davies","year":"2018","unstructured":"\u2022 Davies SJ, Burhan AM, Kim D, Gerretsen P, Graff-Guerrero A, Woo VL, et al. Sequential drug treatment algorithm for agitation and aggression in Alzheimer\u2019s and mixed dementia. J Psychopharmacol. 2018;32(5):509\u201323 Proposes treatment algorithm for BPSD, considering various manifestations of BPSD.","journal-title":"J Psychopharmacol"},{"key":"269_CR70","doi-asserted-by":"crossref","unstructured":"\u2022 Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer\u2019s disease: an international Delphi consensus. Int Psychogeriatr. 2018;1\u20138. Expert consensus regarding treatment considerations for BPSD.","DOI":"10.1017\/S1041610218000534"},{"key":"269_CR71","doi-asserted-by":"crossref","unstructured":"Soto M, Andrieu S, Nourhashemi F, Ousset PJ, Ballard C, Robert P, et al. Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. Int Psychogeriatr. 2014:1\u201317.","DOI":"10.1017\/S1041610214001720"}],"container-title":["Current Geriatrics Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13670-019-0269-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13670-019-0269-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13670-019-0269-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T14:53:48Z","timestamp":1580741628000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13670-019-0269-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["269"],"URL":"https:\/\/doi.org\/10.1007\/s13670-019-0269-1","relation":{},"ISSN":["2196-7865"],"issn-type":[{"value":"2196-7865","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"assertion":[{"value":"22 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Cara McDermott and David Gruenewald declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The contents of this article do not represent the views of the US Department of Veterans Affairs or the US Government.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}